LaSalle Street Capital Management LLC Acquires Shares of 4,576 Eagle Pharmaceuticals, Inc. (EGRX)

LaSalle Street Capital Management LLC acquired a new position in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,576 shares of the specialty pharmaceutical company’s stock, valued at approximately $273,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd bought a new position in Eagle Pharmaceuticals during the 3rd quarter worth approximately $257,000. Iridian Asset Management LLC CT boosted its stake in Eagle Pharmaceuticals by 17.2% during the 3rd quarter. Iridian Asset Management LLC CT now owns 814,214 shares of the specialty pharmaceutical company’s stock worth $48,560,000 after acquiring an additional 119,327 shares during the last quarter. Macquarie Group Ltd. bought a new position in Eagle Pharmaceuticals during the 3rd quarter worth approximately $316,000. Ameriprise Financial Inc. boosted its stake in Eagle Pharmaceuticals by 4.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 138,619 shares of the specialty pharmaceutical company’s stock worth $8,267,000 after acquiring an additional 5,548 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in Eagle Pharmaceuticals by 60.8% during the 3rd quarter. SG Americas Securities LLC now owns 4,511 shares of the specialty pharmaceutical company’s stock worth $269,000 after acquiring an additional 1,706 shares during the last quarter.

WARNING: This article was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://ledgergazette.com/2017/11/19/lasalle-street-capital-management-llc-acquires-shares-of-4576-eagle-pharmaceuticals-inc-egrx.html.

Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) traded up $0.42 during mid-day trading on Friday, reaching $57.40. 191,539 shares of the company’s stock traded hands, compared to its average volume of 308,297. The company has a quick ratio of 5.15, a current ratio of 5.30 and a debt-to-equity ratio of 0.26. The firm has a market cap of $856.52, a P/E ratio of 9.05 and a beta of 1.23. Eagle Pharmaceuticals, Inc. has a 52-week low of $45.05 and a 52-week high of $97.15.

Eagle Pharmaceuticals announced that its Board of Directors has approved a stock repurchase program on Wednesday, August 9th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the specialty pharmaceutical company to repurchase up to 13.3% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its stock is undervalued.

Several research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 31st. Mizuho reduced their price objective on shares of Eagle Pharmaceuticals from $57.00 to $40.00 and set an “underperform” rating on the stock in a research note on Thursday, July 27th. ValuEngine raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. BidaskClub raised shares of Eagle Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 12th. Finally, Piper Jaffray Companies set a $75.00 price objective on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. Eagle Pharmaceuticals has an average rating of “Hold” and an average target price of $62.33.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply